Summit Creek Advisors LLC Makes New $6.43 Million Investment in Artivion, Inc. $AORT

Posted by Brenda Bartman on May 21st, 2026

Summit Creek Advisors LLC bought a new position in shares of Artivion, Inc. (NYSE:AORT – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 140,873 shares of the company’s stock, valued at approximately $6,425,000. Summit Creek Advisors LLC owned 0.30% of Artivion as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. SG Americas Securities LLC lifted its holdings in Artivion by 578.4% during the fourth quarter. SG Americas Securities LLC now owns 39,030 shares of the company’s stock worth $1,780,000 after buying an additional 33,277 shares during the period. Public Sector Pension Investment Board lifted its holdings in Artivion by 23.7% during the third quarter. Public Sector Pension Investment Board now owns 161,970 shares of the company’s stock worth $6,858,000 after buying an additional 30,989 shares during the period. JPMorgan Chase & Co. lifted its holdings in Artivion by 338.2% during the third quarter. JPMorgan Chase & Co. now owns 122,199 shares of the company’s stock worth $5,174,000 after buying an additional 94,312 shares during the period. Kennedy Capital Management LLC lifted its holdings in Artivion by 19.0% during the third quarter. Kennedy Capital Management LLC now owns 437,792 shares of the company’s stock worth $18,536,000 after buying an additional 70,030 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in Artivion by 4.7% during the fourth quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock worth $144,588,000 after buying an additional 141,030 shares during the period. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Artivion Stock Performance

Shares of AORT opened at $22.68 on Thursday. Artivion, Inc. has a 12 month low of $19.16 and a 12 month high of $48.25. The stock has a fifty day moving average price of $33.91 and a 200-day moving average price of $39.88. The company has a current ratio of 3.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.48. The firm has a market cap of $1.10 billion, a PE ratio of 94.49 and a beta of 1.41.

Insider Transactions at Artivion

In related news, SVP Jean F. Holloway sold 8,962 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $38.00, for a total value of $340,556.00. Following the transaction, the senior vice president directly owned 185,095 shares of the company’s stock, valued at $7,033,610. This represents a 4.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John E. Davis sold 4,573 shares of the company’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total value of $172,767.94. Following the completion of the transaction, the insider directly owned 230,794 shares in the company, valued at approximately $8,719,397.32. The trade was a 1.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 133,043 shares of company stock valued at $4,977,158 in the last quarter. Insiders own 6.30% of the company’s stock.

Wall Street Analyst Weigh In

AORT has been the subject of a number of analyst reports. Citizens Jmp lowered their target price on Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a report on Friday, May 8th. Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Needham & Company LLC decreased their price objective on Artivion from $58.00 to $44.00 and set a “buy” rating for the company in a report on Friday, May 8th. LADENBURG THALM/SH SH upgraded Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price objective for the company in a report on Friday, April 10th. Finally, Stifel Nicolaus set a $55.00 price objective on Artivion in a report on Thursday, March 5th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Artivion currently has an average rating of “Moderate Buy” and a consensus price target of $47.83.

Read Our Latest Research Report on AORT

Artivion Company Profile

(Free Report)

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.

Institutional Ownership by Quarter for Artivion (NYSE:AORT)

Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.